PRAX – praxis precision medicines, inc. (US:NASDAQ)
Stock Stats
News
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Guggenheim.
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
A Look At Praxis Precision Medicines (PRAX) Valuation As Analysts Reaffirm Bullish CNS Pipeline Views [Yahoo! Finance]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Needham & Company LLC from $460.00 to $510.00. They now have a "buy" rating on the stock.
Form 4 Praxis Precision Medicin For: Feb 06 Filed by: Arbuckle Stuart A
Form 4 Praxis Precision Medicin For: Feb 06 Filed by: KINDLER JEFFREY B
Form 8-K/A Praxis Precision Medicin For: Feb 06
Form SCHEDULE 13G Praxis Precision Medicin Filed by: FMR LLC
Form 4 Praxis Precision Medicin For: Jan 12 Filed by: Mastrocola Lauren
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.